Following a more than 13% jump in the previous session, Zai Lab Ltd (ZLAB.US) shares continued to climb sharply on Friday, rising over 10% to $23.03.
According to market sources, Citigroup released a report noting that Zai Lab's second-quarter product revenue improved approximately 11% quarter-over-quarter to about $106 million, aligning with the bank's and market expectations. This performance has boosted Citigroup's confidence that the company's China operations can stabilize by the second half of 2026 and resume significant growth by 2027, as per management guidance. The bank has raised its price target for Zai Lab's US-listed shares from $44 to $45.